Pulse Biosciences (NASDAQ:PLSE) Trading Up 9.2% – Should You Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s stock price was up 9.2% on Thursday . The stock traded as high as $26.00 and last traded at $26.1580. Approximately 174,175 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 317,707 shares. The stock had previously closed at $23.96.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on PLSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Tuesday, April 21st. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 20th. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 6th. Finally, Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Pulse Biosciences presently has an average rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Trading Down 9.4%

The company has a market cap of $1.68 billion, a P/E ratio of -22.32 and a beta of 1.63. The business’s 50 day simple moving average is $21.35 and its 200 day simple moving average is $17.80.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Monday, May 4th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. Sell-side analysts anticipate that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insiders Place Their Bets

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $23.64, for a total transaction of $118,200.00. Following the sale, the insider owned 43,298 shares in the company, valued at approximately $1,023,564.72. This trade represents a 10.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Robert W. Duggan acquired 660,233 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the completion of the acquisition, the director owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 74.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its holdings in Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after buying an additional 680 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after buying an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Pulse Biosciences by 13.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company’s stock valued at $70,000 after buying an additional 619 shares in the last quarter. KLP Kapitalforvaltning AS grew its holdings in Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after buying an additional 3,400 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Pulse Biosciences in the second quarter valued at $158,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.